Clinical Trial Update: Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sacituzumab tirumotecan in combination with anlotinib for previously treated extensive-stage small cell lung cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Sichuan University | Conditions: Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Status: NOT_YET_RECRUITING